NO20062090L - Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid - Google Patents

Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid

Info

Publication number: NO20062090L
Authority: NO; Norway
Prior art keywords: polymorphic form; benzamide; difluoro; dihydroxy; propoxy
Prior art date: 2003-10-21

Application number

NO20062090A

Other languages

English (en)

Norwegian (no)

Inventor

Dainius Mackikenas

Thomas Nanninga

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-21

Filing date

2006-05-09

Publication date

2006-07-12

2006-05-09 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2006-07-12 Publication of NO20062090L publication Critical patent/NO20062090L/no

Links

SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 title abstract 2
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Cardiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Obesity (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Biotechnology (AREA)
Orthopedic Medicine & Surgery (AREA)

NO20062090A 2003-10-21 2006-05-09 Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid NO20062090L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51298003P	2003-10-21	2003-10-21
PCT/IB2004/003309 WO2005040098A1 (en)	2003-10-21	2004-10-11	Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Publications (1)

Publication Number	Publication Date
NO20062090L true NO20062090L (no)	2006-07-12

Family

ID=34520067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062090A NO20062090L (no)	2003-10-21	2006-05-09	Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid

Country Status (18)

Country	Link
US (1)	US7060856B2 (pt)
EP (1)	EP1682495A1 (pt)
JP (1)	JP2007509125A (pt)
KR (1)	KR101013932B1 (pt)
CN (1)	CN100594212C (pt)
AR (1)	AR046124A1 (pt)
AU (1)	AU2004283148A1 (pt)
BR (1)	BRPI0415710A (pt)
CA (1)	CA2542210A1 (pt)
CO (1)	CO5690569A2 (pt)
IL (1)	IL174367A0 (pt)
MX (1)	MXPA06004363A (pt)
NO (1)	NO20062090L (pt)
NZ (1)	NZ546011A (pt)
RU (1)	RU2352558C2 (pt)
TW (1)	TW200524584A (pt)
WO (1)	WO2005040098A1 (pt)
ZA (1)	ZA200602250B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2292721T3 (es) *	2001-03-27	2008-03-16	Dainippon Sumitomo Pharma Co., Ltd.	Derivado de isoxazol cristalino y preparacion medica del mismo.
WO2006061712A2 (en) *	2004-12-10	2006-06-15	Pfizer Inc.	Use of mek inhibitors in treating abnormal cell growth
WO2006134469A1 (en) *	2005-06-14	2006-12-21	Warner-Lambert Company Llc	Methods of preparing mek inhibitor
WO2007042885A2 (en) *	2005-10-07	2007-04-19	Pfizer Products Inc.	Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
CA2737461A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care, Inc.	Solute concentration measurement device and related methods
AU2010217760B2 (en)	2009-02-27	2015-04-09	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US9250106B2 (en)	2009-02-27	2016-02-02	Tandem Diabetes Care, Inc.	Methods and devices for determination of flow reservoir volume
US20110152770A1 (en)	2009-07-30	2011-06-23	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
SG10201405568UA (en)	2009-09-08	2014-11-27	Hoffmann La Roche	4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PH12012501361A1 (en)	2009-12-31	2012-10-22	Centro Nac De Investigaciones Oncologicas Cnio	Tricyclic compounds for use as kinase inhibitors
EP2526102B1 (en)	2010-01-22	2017-03-08	Fundación Centro Nacional de Investigaciones Oncológicas Carlos III	Inhibitors of PI3 kinase
WO2011101644A1 (en)	2010-02-18	2011-08-25	Centro Nacional De Investigaciones Oncologicas (Cnio)	Triazolo [4, 5 - b] pyridin derivatives
WO2011121317A1 (en)	2010-04-01	2011-10-06	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
WO2012052745A1 (en)	2010-10-21	2012-04-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	Combinations of pi3k inhibitors with a second anti -tumor agent
WO2012098387A1 (en)	2011-01-18	2012-07-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
CN102649773A (zh) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
CN103841976A (zh)	2011-04-01	2014-06-04	基因泰克公司	Akt和mek抑制剂化合物的组合及其使用方法
CN103841975A (zh)	2011-04-01	2014-06-04	基因泰克公司	Akt抑制剂化合物和厄洛替尼的组合以及使用方法
KR101953210B1 (ko)	2011-05-19	2019-02-28	푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ	단백질 키나아제 억제제로서의 대환식 화합물
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
WO2013005041A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncologicas (Cnio)	Tricyclic compounds for use as kinase inhibitors
WO2013005057A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	New compounds
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103570594A (zh) *	2012-08-01	2014-02-12	苏州迈泰生物技术有限公司	二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
MX2023009560A (es)	2021-02-17	2023-10-25	Springworks Therapeutics Inc	Solidos cristalinos del inhibidor de mek n-((r)-2,3-dihidroxipropo xi)-3,4-difluoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
US11084780B1 (en)	2021-02-17	2021-08-10	Springworks Therapeutics, Inc.	Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
MX2023009555A (es) *	2021-02-17	2023-11-10	Warner Lambert Co	Composiciones de la forma iv esencialmente pura de n-((r)-2,3-dihidroxipropoxi)-3,4-difluoro-2-(2-fluoro-4-yodo-feni lamino)-benzamida y usos de estas.
CN117279630A (zh)	2021-02-17	2023-12-22	斯普林渥克斯治疗股份有限公司	N-((r)-2,3-二羟基丙氧基)-3,4-二氟-2-(2-氟-4-碘-苯基氨基)-苯甲酰胺的可分散制剂及其用途
US11571402B2 (en)	2021-02-17	2023-02-07	Springworks Therapeutics, Inc.	Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en)	2021-02-17	2021-07-20	Warner-Lambert Company Llc	Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11806322B2 (en)	2022-03-17	2023-11-07	Springworks Therapeutics, Inc.	Mirdametinib treatment
EP4493169A4 (en) *	2022-03-17	2026-03-04	Springworks Therapeutics Inc	Fluorinated phenylamine compounds and pharmaceutical compositions
EP4526286A1 (en)	2022-05-17	2025-03-26	Assia Chemical Industries Ltd.	Solid state forms of mirdametinib and process for preparation thereof
KR20250160454A (ko)	2023-03-16	2025-11-13	스프링웍스 테라퓨틱스, 인크.	미르다메티닙의 투여 형태

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA702961B (en) *	1969-05-15	1971-01-27	Nippon Soda Co	Benzohydroxamates,preparations and uses thereof
US5155110A (en)	1987-10-27	1992-10-13	Warner-Lambert Company	Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
WO1998037881A1 (en)	1997-02-28	1998-09-03	Warner Lambert Company	Method of treating or preventing septic shock by administering a mek inhibitor
NZ501277A (en)	1997-07-01	2002-12-20	Warner Lambert Co	-2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL132840A (en)	1997-07-01	2004-12-15	Warner Lambert Co	Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
GB9726851D0 (en) *	1997-12-19	1998-02-18	Zeneca Ltd	Human signal transduction serine/threonine kinase
US6150401A (en)	1998-01-06	2000-11-21	The General Hospital Corporation	Use of MEK1 inhibitors as protective agents against damage due to ischemia
JP2002531539A (ja)	1998-12-04	2002-09-24	ニューロサーチ、アクティーゼルスカブ	イオンチャネル調節剤
WO2000035435A1 (en)	1998-12-15	2000-06-22	Warner-Lambert Company	Use of a mek inhibitor for preventing transplant rejection
EP1143957A3 (en)	1998-12-16	2002-02-27	Warner-Lambert Company	Treatment of arthritis with mek inhibitors
ES2253928T3 (es)	1998-12-22	2006-06-01	Warner-Lambert Company Llc	Quimioterapia de combinacion que comprende un inhibidor mitotico y un inhibidor mek.
EP1140062B1 (en)	1999-01-07	2005-04-06	Warner-Lambert Company LLC	Treatment of asthma with mek inhibitors
IL144103A0 (en)	1999-01-07	2002-05-23	Warner Lambert Co	Antiviral method using mek inhibitors
WO2000041505A2 (en)	1999-01-13	2000-07-20	Warner-Lambert Company	Anthranilic acid derivatives
AU2482700A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	1-heterocycle substituted diarylamines
AU2201500A (en)	1999-01-13	2000-08-01	Warner-Lambert Company	Benzenesulfonamide derivatives and their use as mek inhibitors
JP2002534497A (ja)	1999-01-13	2002-10-15	ワーナー−ランバート・カンパニー	スルホヒドロキサム酸およびスルホヒドロキサメートおよびｍｅｋ阻害剤としてのその使用
CA2348236A1 (en)	1999-01-13	2000-07-20	Stephen Douglas Barrett	4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
JP2001055376A (ja)	1999-01-13	2001-02-27	Warner Lambert Co	ジアリールアミン
HRP20010524A2 (en) *	1999-01-13	2002-08-31	Warner Lambert Co	Benzoheterocycles and their use as mek inhibitors
CN1365277A (zh)	1999-07-16	2002-08-21	沃尼尔·朗伯公司	使用mek抑制剂治疗慢性疼痛的方法
CN1373660A (zh)	1999-07-16	2002-10-09	沃尼尔·朗伯公司	使用mek抑制剂治疗慢性疼痛的方法
KR20020015379A (ko)	1999-07-16	2002-02-27	로즈 암스트롱, 크리스틴 에이. 트러트웨인	엠이케이 억제제를 사용하는 만성 동통의 치료방법
EP1246823A1 (en)	1999-12-28	2002-10-09	Pharmacopeia, Inc.	Pyrimidine and triazine kinase inhibitors
CA2403017A1 (en)	2000-03-15	2001-09-20	Warner-Lambert Company	5-amide substituted diarylamines as mex inhibitors
DE10017480A1 (de) *	2000-04-07	2001-10-11	Transmit Technologietransfer	Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
CA2416685C (en) *	2000-07-19	2008-10-07	Warner-Lambert Company	Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
JP2004507518A (ja)	2000-08-25	2004-03-11	ワーナー−ランバート・カンパニー・エルエルシー	Ｎ−アリール−アントラニル酸及びその誘導体の製造法
BR0113760A (pt) *	2000-09-08	2003-07-15	Ono Pharmaceutical Co	Novo cristal de n-hidróxi-2-(s)-metil-5-etoximetóxi-4 (s)-[n-(4fenóxifenilcarbonil) amino] pentamida e um processo para preparação como um agente farmacêutico compreendendo o mesmo como ingrediente ativo
WO2002069960A2 (en)	2001-03-06	2002-09-12	Axxima Pharmaceuticals Ag	Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
WO2002076496A1 (en)	2001-03-22	2002-10-03	Van Andel Institute	Anthrax lethal factor inhibits tumor growth and angiogenesis
IL149462A0 (en) *	2001-05-09	2002-11-10	Warner Lambert Co	Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002348791A1 (en) *	2001-12-21	2003-07-09	Warner-Lambert Company Llc	Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
JP2005515253A (ja)	2002-01-23	2005-05-26	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル
DOP2003000556A (es)	2002-01-23	2003-10-31	Warner Lambert Co	Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
AU2003274576A1 (en) *	2002-11-15	2004-06-15	Warner-Lambert Company Llc	Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer

2004
- 2004-10-11 EP EP04769603A patent/EP1682495A1/en not_active Withdrawn
- 2004-10-11 WO PCT/IB2004/003309 patent/WO2005040098A1/en not_active Ceased
- 2004-10-11 AU AU2004283148A patent/AU2004283148A1/en not_active Abandoned
- 2004-10-11 RU RU2006113437/04A patent/RU2352558C2/ru not_active IP Right Cessation
- 2004-10-11 KR KR1020067007613A patent/KR101013932B1/ko not_active Expired - Fee Related
- 2004-10-11 MX MXPA06004363A patent/MXPA06004363A/es unknown
- 2004-10-11 JP JP2006536192A patent/JP2007509125A/ja active Pending
- 2004-10-11 BR BRPI0415710-9A patent/BRPI0415710A/pt not_active IP Right Cessation
- 2004-10-11 NZ NZ546011A patent/NZ546011A/en unknown
- 2004-10-11 CN CN200480030534A patent/CN100594212C/zh not_active Expired - Fee Related
- 2004-10-11 CA CA002542210A patent/CA2542210A1/en not_active Abandoned
- 2004-10-19 AR ARP040103782A patent/AR046124A1/es not_active Application Discontinuation
- 2004-10-20 TW TW093131810A patent/TW200524584A/zh unknown
- 2004-10-20 US US10/969,681 patent/US7060856B2/en not_active Expired - Fee Related
2006
- 2006-03-16 IL IL174367A patent/IL174367A0/en unknown
- 2006-03-17 ZA ZA200602250A patent/ZA200602250B/en unknown
- 2006-04-20 CO CO06037639A patent/CO5690569A2/es not_active Application Discontinuation
- 2006-05-09 NO NO20062090A patent/NO20062090L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2542210A1 (en)	2005-05-06
HK1093483A1 (en)	2007-03-02
EP1682495A1 (en)	2006-07-26
US20050085550A1 (en)	2005-04-21
AU2004283148A1 (en)	2005-05-06
JP2007509125A (ja)	2007-04-12
US7060856B2 (en)	2006-06-13
KR101013932B1 (ko)	2011-02-14
MXPA06004363A (es)	2006-06-14
KR20060080230A (ko)	2006-07-07
RU2006113437A (ru)	2006-08-27
BRPI0415710A (pt)	2006-12-19
CN100594212C (zh)	2010-03-17
NZ546011A (en)	2009-09-25
WO2005040098A1 (en)	2005-05-06
CN1867543A (zh)	2006-11-22
TW200524584A (en)	2005-08-01
CO5690569A2 (es)	2006-10-31
ZA200602250B (en)	2007-05-30
AR046124A1 (es)	2005-11-23
RU2352558C2 (ru)	2009-04-20
IL174367A0 (en)	2006-08-01

Legal Events

Date	Code	Title	Description
2009-05-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20062090L (no)	2006-07-12	Polymorf form av N-[(R)-2,3-dihydroksy-propksy]-3,4-difluor-2-(2-fluor-4-iodfenylamino)-benzamid
NO20045065L (no)	2005-01-07	Nytt formatsalt av o-desmetyl-venlafaxin
EA200300873A1 (ru)	2003-12-25	Новая соль сукцинат o-десметилвенлафаксина
DK1414428T3 (da)	2009-08-31	Histondeacetylaseenzym-inhiberende derivater af hydroxamsyre som hidtil ukendt cytokinsyntese-inhiberende anti-inflammatoriske lægemidler
NO20053846L (no)	2005-08-16	Fremgangsmate for a modifisere legemiddel-krystalldannelse
NO20053088L (no)	2005-06-23	Farmasoytisk preparat inneholdende en beta-3-adrenoseptoragonist og en serotonin og/eller norepinefrin-gjenopptakelsesinhibitor og anvendelse av nevnte preparat for behandling av blaeredysfunksjon.
TW200716520A (en)	2007-05-01	3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
DK1446380T3 (da)	2010-01-04	Formoteroltartrafremgangsmåde og polymorf
BRPI0410959A (pt)	2006-07-04	composição farmacêutica contendo inibidor de histona desacetilase
NO20054018L (no)	2005-08-30	Intranasal formulering av rotigotin
NO20042811L (no)	2004-07-05	Substituerte henzoksazoler og analoger som estrogene midler
IL192233A0 (en)	2008-12-29	Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a subsituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing them
NO20045486L (no)	2005-02-02	Nye forbindelser og deres anvendelse
NO20040268L (no)	2004-03-23	Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
ATE325135T1 (de)	2006-06-15	2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
SE0101322D0 (sv)	2001-04-12	Novel compounds
NO20052698L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
ATE547400T1 (de)	2012-03-15	N-alkylierte diaminopropanderivate als modulatoren der chemokinrezeptoraktivität
NO20063308L (no)	2006-09-12	Kombinasjon av flupirtin og tramadol
BRPI0412459A (pt)	2006-10-17	composto tendo ação anti-hcv e seu método de produção
MX2023009559A (es)	2023-10-25	Formulaciones dispersables de n-((r)-2,3-dihidroxipropoxi)-3,4-dif luoro-2-(2-fluoro-4-yodo-fenilamino)-benzamida y sus usos.
NO995676L (no)	1999-11-19	Isoftalamid derivat som gul polymorf
EA200300771A1 (ru)	2004-02-26	Новая соль бензоилгуанидина
AR052161A1 (es)	2007-03-07	Derivados de n-[1-(cianometil-carbamoil)-ciclohexil]-4-(4-propil-piperazin-1-il)-benzamida
NO20031030D0 (no)	2003-03-05	Nye krystaller av N-hydroksy-2(S)-metyl-5-etoksymetoksy-4(S)- [N-(4-fenoksyfenylkarbonyl)amino]pentanamid, fremgangsmåte for deresfremstilling og medisinerinneholdende krystallene som den aktive bestanddel